Hdt Bio

Hdt Bio company information, Employees & Contact Information

Explore related pages

Related company profiles:

HDT Bio is a vaccine and immunotherapy Biotechnology company developing drugs for immunotherapy of cancers and infectious diseases with next-generation approaches designed to enable the body’s immune system to prevent and cure disease. We have engineered our technologies to Access, Activate, and Amplify the immune system’s natural ability to create antibodies and T-cells that fight cancer and infectious diseases such as SARS-CoV-2. We are developing multiple product candidates from our proprietary discovery platforms, including LION™, which has the potential to provide health benefits to a broad patient population. Our products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies. HDT Bio offers a comprehensive compensation plan, which includes health insurance for employees and dependents (inclusive of multiple plants to choose from, including a $0 premium plan with HSA and company contribution), generous PTO (11 observed holidays and week-long year-end closure), stock options with Carta Tax Advisory for equity and tax support, flexible spending accounts (FSAs), commuting benefits (ORCA or paid parking), and retirement benefits with company match. HDT Bio Corp. is an equal opportunity employer committed to a diverse and inclusive workforce.

Company Details

Employees
66
Founded
-
Address
1150 Eastlake Ave E,
Email
in****@****hdt.bio
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
hdt.bio
HQ
Seattle, Washington
Looking for a particular Hdt Bio employee's phone or email?

Hdt Bio Questions

News

FDA Greenlights HDT Bio's First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease - PR Newswire

FDA Greenlights HDT Bio's First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease PR Newswire

Exclusive: RFK Jr cancelled mRNA research — but the US military is still funding it - Nature

Exclusive: RFK Jr cancelled mRNA research — but the US military is still funding it Nature

RNA Therapeutics and Vaccines Market Industry Trends & Forecasts to 2035, with Profiles of Alphavax, Arcturus Therapeutics, aTyr Pharma, Gritstone Bio, HDT Bio, MiNA Therapeutics, & VLP Therapeutics - ResearchAndMarkets.com - Business Wire

RNA Therapeutics and Vaccines Market Industry Trends & Forecasts to 2035, with Profiles of Alphavax, Arcturus Therapeutics, aTyr Pharma, Gritstone Bio, HDT Bio, MiNA Therapeutics, & VLP Therapeutics - ResearchAndMarkets.com Business Wire

Industry Insights with HDT Bio | D2R | DNA to RNA - McGill University

Industry Insights with HDT Bio | D2R | DNA to RNA McGill University

US HHS cancels 22 BARDA mRNA vaccine contracts - BioWorld MedTech

US HHS cancels 22 BARDA mRNA vaccine contracts BioWorld MedTech

A replicating RNA vaccine confers protection against Crimean-Congo hemorrhagic fever in cynomolgus macaques - The Lancet

A replicating RNA vaccine confers protection against Crimean-Congo hemorrhagic fever in cynomolgus macaques The Lancet

HHS mRNA Vaccine Wind-Down Has Limited Impact (And One Contract Isn’t Even mRNA) - Citeline News & Insights

HHS mRNA Vaccine Wind-Down Has Limited Impact (And One Contract Isn’t Even mRNA) Citeline News & Insights

RFK Jr shuts down mRNA vaccine funding - The Pharma Letter

RFK Jr shuts down mRNA vaccine funding The Pharma Letter

MalarVx licenses HDT Bio's repRNA/LION™ Technology for Novel Malaria Vaccine - PR Newswire

MalarVx licenses HDT Bio's repRNA/LION™ Technology for Novel Malaria Vaccine PR Newswire

HDT Bio and Gennova dose healthy subjects in Covid-19 trial in India - Clinical Trials Arena

HDT Bio and Gennova dose healthy subjects in Covid-19 trial in India Clinical Trials Arena

The Secret World of mRNA: HDT Bio Corp v. Emcure and Access to Next-Gen mRNA - Petrie-Flom Center

The Secret World of mRNA: HDT Bio Corp v. Emcure and Access to Next-Gen mRNA Petrie-Flom Center

NIH-backed HDT Bio sues Indian partner for $950M, alleging it stole trade secrets - Fierce Biotech

NIH-backed HDT Bio sues Indian partner for $950M, alleging it stole trade secrets Fierce Biotech

Riding the mRNA wave, HDT Bio closes in on cancer-fighting vaccine - Pharma Voice

Riding the mRNA wave, HDT Bio closes in on cancer-fighting vaccine Pharma Voice

Emcure, HDT settle legal fight over COVID vaccine technology - Reuters

Emcure, HDT settle legal fight over COVID vaccine technology Reuters

UTMB and HDT Bio receive US funding for vaccine development - Pharmaceutical Technology

UTMB and HDT Bio receive US funding for vaccine development Pharmaceutical Technology

HDT Bio gets FDA approval for Phase I Covid-19 vaccine trial in US - Clinical Trials Arena

HDT Bio gets FDA approval for Phase I Covid-19 vaccine trial in US Clinical Trials Arena

HDT Bio receives Emergency Use Approval for Covid-19 vaccine in India - Pharmaceutical Technology

HDT Bio receives Emergency Use Approval for Covid-19 vaccine in India Pharmaceutical Technology

HDT Bio Receives $749,000 EZBAA Contract and Partners with BARDA Under Project NextGen's Enabler's Program - PR Newswire

HDT Bio Receives $749,000 EZBAA Contract and Partners with BARDA Under Project NextGen's Enabler's Program PR Newswire

HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative - PR Newswire

HDT Bio to Help Spearhead RNA Vaccine Development in National Pandemic Preparedness Initiative PR Newswire

HDT Bio and Quratis to jointly develop Covid-19 vaccine in Asia - Pharmaceutical Technology

HDT Bio and Quratis to jointly develop Covid-19 vaccine in Asia Pharmaceutical Technology

Company Profile for HDT Bio Corp. - Business Wire

Company Profile for HDT Bio Corp. Business Wire

HDT Bio dose first subjects in Phase I Covid-19 vaccine trial - Clinical Trials Arena

HDT Bio dose first subjects in Phase I Covid-19 vaccine trial Clinical Trials Arena

HDT Bio Demonstrates RNA Vaccines Matched to SARS-CoV2 Variants Protect Against Infection of Upper Airways, Important for Preventing Transmission - Business Wire

HDT Bio Demonstrates RNA Vaccines Matched to SARS-CoV2 Variants Protect Against Infection of Upper Airways, Important for Preventing Transmission Business Wire

$749,000 Contract Awarded for Next Generation RNA Vaccine Production - Vax-Before-Travel

$749,000 Contract Awarded for Next Generation RNA Vaccine Production Vax-Before-Travel

NIH grants up to $100M yearly for pandemic preparedness network - Fierce Biotech

NIH grants up to $100M yearly for pandemic preparedness network Fierce Biotech

A replicating RNA vaccine protects against severe fever with thrombocytopenia syndrome virus infection in mice - Nature

A replicating RNA vaccine protects against severe fever with thrombocytopenia syndrome virus infection in mice Nature

Lawsuit says India's Emcure stole COVID-19 vaccine secrets for IPO - Reuters

Lawsuit says India's Emcure stole COVID-19 vaccine secrets for IPO Reuters

US Pharma Firm HDT Bio Begins Phase III Trial Of Covid Vaccine In India - NDTV

US Pharma Firm HDT Bio Begins Phase III Trial Of Covid Vaccine In India NDTV

A gH/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge - Nature

A gH/gL-encoding replicon vaccine elicits neutralizing antibodies that protect humanized mice against EBV challenge Nature

Emcure, Gennova settle legal dispute with US-based HDT Bio, sign agreement - Business Standard

Emcure, Gennova settle legal dispute with US-based HDT Bio, sign agreement Business Standard

U.S. Military Continues mRNA Vaccine Research after RFK, Jr., Cuts Funding - Yahoo

U.S. Military Continues mRNA Vaccine Research after RFK, Jr., Cuts Funding Yahoo

NIH funds new research to combat emerging viruses - News-Medical

NIH funds new research to combat emerging viruses News-Medical

Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine - Nature

Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine Nature

COVID-19 vaccine has hefty response in nonhuman primates - UW Medicine | Newsroom

COVID-19 vaccine has hefty response in nonhuman primates UW Medicine | Newsroom

A replicating RNA vaccine confers protection in a rhesus macaque model of Crimean-Congo hemorrhagic fever - Nature

A replicating RNA vaccine confers protection in a rhesus macaque model of Crimean-Congo hemorrhagic fever Nature

Editorial: Emerging Concepts of Innate Immune Responses to Neglected Tropical Diseases - Frontiers

Editorial: Emerging Concepts of Innate Immune Responses to Neglected Tropical Diseases Frontiers

HHS halts $500m in mRNA vaccine investment, reshaping biotech funding landscape - BioXconomy

HHS halts $500m in mRNA vaccine investment, reshaping biotech funding landscape BioXconomy

COVID-19 shots with Seattle origins reach regulatory milestones in South Korea, India - GeekWire

COVID-19 shots with Seattle origins reach regulatory milestones in South Korea, India GeekWire

CRISPR’s cardio catch-all drives a biotech’s broad potential - Pharma Voice

CRISPR’s cardio catch-all drives a biotech’s broad potential Pharma Voice

Albert Einstein College of Medicine Receives Major Federal Grant to Help Lead National Effort for Pandemic Preparedness - Montefiore Einstein Now

Albert Einstein College of Medicine Receives Major Federal Grant to Help Lead National Effort for Pandemic Preparedness Montefiore Einstein Now

US firm sues Emcure for $950 million over 'stealing' trade secrets - Times of India

US firm sues Emcure for $950 million over 'stealing' trade secrets Times of India

New study reveals self-replicating RNA and novel vaccine delivery technology demonstrate enhanced safety and efficacy - Medical Xpress

New study reveals self-replicating RNA and novel vaccine delivery technology demonstrate enhanced safety and efficacy Medical Xpress

HHS ends $500M in BARDA‑funded mRNA vaccine developments - TechTarget

HHS ends $500M in BARDA‑funded mRNA vaccine developments TechTarget

RFK Jr.'s mRNA vaccine funding cut: Are NY scientists working on mRNA research affected? - Lohud

RFK Jr.'s mRNA vaccine funding cut: Are NY scientists working on mRNA research affected? Lohud

Gennova's mRNA vaccine in legal storm after HDT Bio Corp sues Emcure - Business Standard

Gennova's mRNA vaccine in legal storm after HDT Bio Corp sues Emcure Business Standard

A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques - Frontiers

A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques Frontiers

Intramuscular delivery of formulated RNA encoding six linked nanobodies is highly protective for exposures to three Botulinum neurotoxin serotypes | Scientific Reports - Nature

Intramuscular delivery of formulated RNA encoding six linked nanobodies is highly protective for exposures to three Botulinum neurotoxin serotypes | Scientific Reports Nature

HHS ends mRNA vaccine projects after review - The Poultry Site

HHS ends mRNA vaccine projects after review The Poultry Site

Emcure, Gennova bury hatchet with HDT Bio Corp; team up again for mRNA vaccines - BusinessLine

Emcure, Gennova bury hatchet with HDT Bio Corp; team up again for mRNA vaccines BusinessLine

HHS scraps further work on life-saving mRNA vaccine platform - CIDRAP

HHS scraps further work on life-saving mRNA vaccine platform CIDRAP

RFK Jr. Pulls Back on U.S. Investment in mRNA Vaccine Research - NOTUS — News of the United States

RFK Jr. Pulls Back on U.S. Investment in mRNA Vaccine Research NOTUS — News of the United States

RNA Therapeutics Market Size is expected to reach US$ 948 Million by 2031, Report by CoherentMI - Yahoo Finance

RNA Therapeutics Market Size is expected to reach US$ 948 Million by 2031, Report by CoherentMI Yahoo Finance

Kennedy says BARDA to cancel work on future mRNA vaccines, claiming they ‘don’t perform well’ - Endpoints News

Kennedy says BARDA to cancel work on future mRNA vaccines, claiming they ‘don’t perform well’ Endpoints News

Keeping covid vaccines cold isn’t easy. These ideas could help. - MIT Technology Review

Keeping covid vaccines cold isn’t easy. These ideas could help. MIT Technology Review

Emcure and its subsidiary Gennova settle legal dispute with HDT Bio over mRNA technology - The Economic Times

Emcure and its subsidiary Gennova settle legal dispute with HDT Bio over mRNA technology The Economic Times

U.S. defense supports mRNA vaccine development as health department withdraws funding - CHOSUNBIZ - Chosun Biz

U.S. defense supports mRNA vaccine development as health department withdraws funding - CHOSUNBIZ Chosun Biz

‘We’ve been instrumental’: How Seattle became a hub for COVID-19 vaccine research - GeekWire

‘We’ve been instrumental’: How Seattle became a hub for COVID-19 vaccine research GeekWire

Emcure's Gennova Biopharmaceuticals amicably resolves all legal disputes with HDT Bio Corp - ET HealthWorld

Emcure's Gennova Biopharmaceuticals amicably resolves all legal disputes with HDT Bio Corp ET HealthWorld

Emcure wins dismissal of US lawsuit over COVID vaccine trade secrets - Medical Dialogues

Emcure wins dismissal of US lawsuit over COVID vaccine trade secrets Medical Dialogues

Judge Won't Toss $950M COVID-19 Vax Trade Secrets Row - Law360

Judge Won't Toss $950M COVID-19 Vax Trade Secrets Row Law360

RNA vaccination in rabbit mothers confers benefits to offspring in the womb, shows study - Phys.org

RNA vaccination in rabbit mothers confers benefits to offspring in the womb, shows study Phys.org

BIX Korea 2024: Promise of mRNA technology for cell and gene therapy - BioWorld MedTech

BIX Korea 2024: Promise of mRNA technology for cell and gene therapy BioWorld MedTech

UW Medicine lays out road to a Covid-19 vaccine - The Business Journals

UW Medicine lays out road to a Covid-19 vaccine The Business Journals

HHS Cancels 22 MRNA Vaccine Development Contracts - NTD News

HHS Cancels 22 MRNA Vaccine Development Contracts NTD News

'Wrongly joined in lawsuit': Emcure on claims it stole US company's vaccine tech - theweek.in

'Wrongly joined in lawsuit': Emcure on claims it stole US company's vaccine tech theweek.in

Coronavirus vaccine shows promising immune response in animals, University of Washington researchers say - KUOW

Coronavirus vaccine shows promising immune response in animals, University of Washington researchers say KUOW

Host Decoy Trap (HDT) with cattle odour is highly effective for collection of exophagic malaria vectors - Parasites & Vectors

Host Decoy Trap (HDT) with cattle odour is highly effective for collection of exophagic malaria vectors Parasites & Vectors

Optimised approaches to biofuels production in existing refineries | 4REFINERY Project | Results in Brief | H2020 - CORDIS

Optimised approaches to biofuels production in existing refineries | 4REFINERY Project | Results in Brief | H2020 CORDIS

Clinical trials for novel coronavirus vaccine will take place at Seattle research institute - The Seattle Times

Clinical trials for novel coronavirus vaccine will take place at Seattle research institute The Seattle Times

Emcure Pharma seeks to raise Rs 1,952 cr through IPO, issue opens July 3 - Business Standard

Emcure Pharma seeks to raise Rs 1,952 cr through IPO, issue opens July 3 Business Standard

US Military Still Financing mRNA Vaccine Studies - Talk 99.5

US Military Still Financing mRNA Vaccine Studies Talk 99.5

Top Hdt Bio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant